vs
MANITOWOC CO INC（MTW）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是MANITOWOC CO INC的1.1倍（$772.1M vs $677.1M），Revvity净利率更高（12.7% vs 1.0%，领先11.7%），MANITOWOC CO INC同比增速更快（13.6% vs 5.9%），Revvity自由现金流更多（$161.8M vs $78.3M），过去两年MANITOWOC CO INC的营收复合增速更高（16.9% vs 9.0%）
马尼托瓦克公司是一家美国工程机械制造企业，创立于1902年，核心产品为起重机械，历史上曾生产商用制冷设备与船舶设备。公司通过全资子公司，围绕Grove、马尼托瓦克、Potain等多个品牌，设计、生产、销售移动式伸缩臂起重机、塔式起重机、履带式起重机等设备，并提供相关售后服务支持。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
MTW vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.1倍
$677.1M
营收增速更快
MTW
高出7.8%
5.9%
净利率更高
RVTY
高出11.7%
1.0%
自由现金流更多
RVTY
多$83.5M
$78.3M
两年增速更快
MTW
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $677.1M | $772.1M |
| 净利润 | $7.0M | $98.4M |
| 毛利率 | 16.7% | — |
| 营业利润率 | 3.0% | 14.5% |
| 净利率 | 1.0% | 12.7% |
| 营收同比 | 13.6% | 5.9% |
| 净利润同比 | -87.7% | 3.9% |
| 每股收益（稀释后） | $0.20 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MTWRVTY
| Q4 25 | $677.1M | $772.1M | ||
| Q3 25 | $553.4M | $698.9M | ||
| Q2 25 | $539.5M | $720.3M | ||
| Q1 25 | $470.9M | $664.8M | ||
| Q4 24 | $596.0M | $729.4M | ||
| Q3 24 | $524.8M | $684.0M | ||
| Q2 24 | $562.1M | $691.7M | ||
| Q1 24 | $495.1M | $649.9M |
净利润MTWRVTY
| Q4 25 | $7.0M | $98.4M | ||
| Q3 25 | $5.0M | $46.7M | ||
| Q2 25 | $1.5M | $53.9M | ||
| Q1 25 | $-6.3M | $42.2M | ||
| Q4 24 | $56.7M | $94.6M | ||
| Q3 24 | $-7.0M | $94.4M | ||
| Q2 24 | $1.6M | $55.4M | ||
| Q1 24 | $4.5M | $26.0M |
毛利率MTWRVTY
| Q4 25 | 16.7% | — | ||
| Q3 25 | 18.5% | 53.6% | ||
| Q2 25 | 18.4% | 54.5% | ||
| Q1 25 | 19.1% | 56.5% | ||
| Q4 24 | 16.0% | — | ||
| Q3 24 | 16.7% | 56.3% | ||
| Q2 24 | 17.7% | 55.7% | ||
| Q1 24 | 18.7% | 54.6% |
营业利润率MTWRVTY
| Q4 25 | 3.0% | 14.5% | ||
| Q3 25 | 3.3% | 11.7% | ||
| Q2 25 | 1.8% | 12.6% | ||
| Q1 25 | 1.1% | 10.9% | ||
| Q4 24 | 2.7% | 16.3% | ||
| Q3 24 | 1.4% | 14.3% | ||
| Q2 24 | 2.3% | 12.4% | ||
| Q1 24 | 3.1% | 6.8% |
净利率MTWRVTY
| Q4 25 | 1.0% | 12.7% | ||
| Q3 25 | 0.9% | 6.7% | ||
| Q2 25 | 0.3% | 7.5% | ||
| Q1 25 | -1.3% | 6.4% | ||
| Q4 24 | 9.5% | 13.0% | ||
| Q3 24 | -1.3% | 13.8% | ||
| Q2 24 | 0.3% | 8.0% | ||
| Q1 24 | 0.9% | 4.0% |
每股收益（稀释后）MTWRVTY
| Q4 25 | $0.20 | $0.86 | ||
| Q3 25 | $0.14 | $0.40 | ||
| Q2 25 | $0.04 | $0.46 | ||
| Q1 25 | $-0.18 | $0.35 | ||
| Q4 24 | $1.60 | $0.77 | ||
| Q3 24 | $-0.20 | $0.77 | ||
| Q2 24 | $0.04 | $0.45 | ||
| Q1 24 | $0.12 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $77.3M | $919.9M |
| 总债务越低越好 | $447.1M | — |
| 股东权益账面价值 | $695.2M | $7.3B |
| 总资产 | $1.8B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.64× | — |
8季度趋势，按日历期对齐
现金及短期投资MTWRVTY
| Q4 25 | $77.3M | $919.9M | ||
| Q3 25 | $39.7M | $931.4M | ||
| Q2 25 | $32.9M | $991.8M | ||
| Q1 25 | $41.4M | $1.1B | ||
| Q4 24 | $48.0M | $1.2B | ||
| Q3 24 | $22.9M | $1.2B | ||
| Q2 24 | $38.1M | $2.0B | ||
| Q1 24 | $31.5M | $1.7B |
总债务MTWRVTY
| Q4 25 | $447.1M | — | ||
| Q3 25 | $479.9M | — | ||
| Q2 25 | $459.8M | — | ||
| Q1 25 | $381.4M | — | ||
| Q4 24 | $377.1M | — | ||
| Q3 24 | $426.7M | — | ||
| Q2 24 | $406.3M | — | ||
| Q1 24 | $372.7M | — |
股东权益MTWRVTY
| Q4 25 | $695.2M | $7.3B | ||
| Q3 25 | $682.7M | $7.4B | ||
| Q2 25 | $681.3M | $7.6B | ||
| Q1 25 | $651.6M | $7.6B | ||
| Q4 24 | $640.1M | $7.7B | ||
| Q3 24 | $607.6M | $7.9B | ||
| Q2 24 | $592.3M | $7.9B | ||
| Q1 24 | $596.0M | $7.8B |
总资产MTWRVTY
| Q4 25 | $1.8B | $12.2B | ||
| Q3 25 | $1.9B | $12.1B | ||
| Q2 25 | $1.9B | $12.4B | ||
| Q1 25 | $1.8B | $12.4B | ||
| Q4 24 | $1.7B | $12.4B | ||
| Q3 24 | $1.8B | $12.8B | ||
| Q2 24 | $1.7B | $13.4B | ||
| Q1 24 | $1.8B | $13.4B |
负债/权益比MTWRVTY
| Q4 25 | 0.64× | — | ||
| Q3 25 | 0.70× | — | ||
| Q2 25 | 0.67× | — | ||
| Q1 25 | 0.59× | — | ||
| Q4 24 | 0.59× | — | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 0.69× | — | ||
| Q1 24 | 0.63× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $91.1M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $78.3M | $161.8M |
| 自由现金流率自由现金流/营收 | 11.6% | 21.0% |
| 资本支出强度资本支出/营收 | 1.9% | 2.6% |
| 现金转化率经营现金流/净利润 | 13.01× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $-15.3M | $509.4M |
8季度趋势，按日历期对齐
经营现金流MTWRVTY
| Q4 25 | $91.1M | $182.0M | ||
| Q3 25 | $-14.1M | $138.5M | ||
| Q2 25 | $-67.7M | $134.3M | ||
| Q1 25 | $12.9M | $128.2M | ||
| Q4 24 | $112.4M | $174.2M | ||
| Q3 24 | $-43.6M | $147.9M | ||
| Q2 24 | $11.0M | $158.6M | ||
| Q1 24 | $-30.6M | $147.6M |
自由现金流MTWRVTY
| Q4 25 | $78.3M | $161.8M | ||
| Q3 25 | $-22.0M | $120.0M | ||
| Q2 25 | $-73.7M | $115.5M | ||
| Q1 25 | $2.1M | $112.2M | ||
| Q4 24 | $101.1M | $149.8M | ||
| Q3 24 | $-52.9M | $125.6M | ||
| Q2 24 | $-1.9M | $136.6M | ||
| Q1 24 | $-42.8M | $129.7M |
自由现金流率MTWRVTY
| Q4 25 | 11.6% | 21.0% | ||
| Q3 25 | -4.0% | 17.2% | ||
| Q2 25 | -13.7% | 16.0% | ||
| Q1 25 | 0.4% | 16.9% | ||
| Q4 24 | 17.0% | 20.5% | ||
| Q3 24 | -10.1% | 18.4% | ||
| Q2 24 | -0.3% | 19.7% | ||
| Q1 24 | -8.6% | 20.0% |
资本支出强度MTWRVTY
| Q4 25 | 1.9% | 2.6% | ||
| Q3 25 | 1.4% | 2.6% | ||
| Q2 25 | 1.1% | 2.6% | ||
| Q1 25 | 2.3% | 2.4% | ||
| Q4 24 | 1.9% | 3.4% | ||
| Q3 24 | 1.8% | 3.3% | ||
| Q2 24 | 2.3% | 3.2% | ||
| Q1 24 | 2.5% | 2.7% |
现金转化率MTWRVTY
| Q4 25 | 13.01× | 1.85× | ||
| Q3 25 | -2.82× | 2.97× | ||
| Q2 25 | -45.13× | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | 1.98× | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | 6.88× | 2.87× | ||
| Q1 24 | -6.80× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MTW
| US | $344.5M | 51% |
| Europe | $193.8M | 29% |
| Other Countries | $138.8M | 20% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
